3Y Capital
三奕资本
3Y Capital (三奕资本) is a Chinese investment fund, but elsewhere's corpus contains no dedicated profile of it — no founding details, AUM, or strategy on record. It surfaces only as a participant in two deals: it followed on in BizSeer Technology's nearly RMB 200 million Series C in October 2022, alongside Sequoia China and Shunwei, led by CDH-affiliated Chenyi ; and as an existing shareholder it continued investing in Tianchen Bio's over-RMB-200-million Series C in June 2025, co-led by HighLight Capital and Qiming Venture Partners . For a fuller picture, see the result list below.
AI-generated — may contain errors, please verify.
Coverage
Qiming Star | Tianchen Biotech Raises Over 200 Million Yuan in Series C, Co-Led by Qiming Venture Partners
TianChen Bio is committed to setting the industry benchmark in allergic diseases and complement-mediated diseases, continuously driving treatment innovation to deliver breakthrough therapies with greater clinical value and accessibility for patients worldwide.
The "Pinduoduo" of M&A: A New Model of Entrepreneurship Built for Investors | Entering the Game
It was a hit in the US for three decades, but remains niche in China.
Bishijia Technology Closes Nearly RMB 200 Million Series C Round, Unveils Next-Generation Intelligent Operations Product Suite
Accelerate the deployment of intelligent operations platforms across more industries.
